Editorial review

Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.

Yahoo Health Flags Pre-Treatment Questions for Ketamine Patients

Yahoo Health published a guide on October 7, 2026, encouraging people considering ketamine for depression to prepare a list of questions before their first appointment. The original article is aimed at a general audience and does not specify which form of ketamine a reader might be offered. That detail matters more than most guides let on, because the questions worth asking change depending on whether you are being offered an oral tablet, a sublingual troche, a nasal spray, or an IV infusion.

This piece builds on that framing with analysis specific to oral ketamine tablets, since dosing math, monitoring expectations, and access logistics differ meaningfully by route of administration.

Oral Tablets Metabolize Differently Than Nasal Spray or IV Ketamine

Ketamine taken as an oral tablet or capsule passes through the liver before reaching the bloodstream, a process called first-pass metabolism. Pharmacology literature commonly describes oral ketamine's bioavailability as roughly 20 to 25 percent, compared with close to 100 percent for IV infusions, which means a meaningfully larger oral dose is needed to produce an effect comparable to an infusion. First-pass metabolism also converts a large share of an oral dose into norketamine, an active metabolite with its own effects, so the pharmacological profile of a tablet is not simply a weaker version of an infusion.

Esketamine nasal spray, sold under the brand name Spravato, is the only ketamine-related treatment the FDA has approved specifically for depression, and it is approved only for treatment-resistant depression and depressive symptoms in adults with major depressive disorder with suicidal ideation or behavior. Spravato is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) program, which requires administration in a certified health care setting with at least two hours of monitoring per dose. Oral and sublingual ketamine for depression, by contrast, is prescribed off-label, meaning a clinician is using an FDA-approved drug for a purpose the FDA has not specifically reviewed and approved for that use. Off-label does not mean unsafe or improper, but it does mean the dosing, monitoring, and compounding standards are set by individual clinics rather than a single approved label, which is exactly why asking detailed questions matters more with tablets than with Spravato.

Compare tablet options

Review tablets versus troches, IV infusion, and other routes before deciding what to ask.

Compare options

Key Takeaway

If you are evaluating an oral ketamine tablet or troche for depression in 2026, ask your prescriber these five things specifically: (1) Is this compounded by a licensed, accredited pharmacy, and can you see documentation? (2) How was my starting dose calculated given oral ketamine's lower bioavailability compared to infusions? (3) What blood pressure and dissociation monitoring happens during and after dosing, especially for the first few sessions? (4) Will I be screened for cardiovascular risk factors, a history of psychosis, substance use, or bladder symptoms before starting? (5) Is this treatment paired with a structured therapy plan, and what does the follow-up schedule look like over the first 4 to 6 weeks?

Screening Questions Oral Tablet Patients Shouldn't Skip

Because oral ketamine is off-label for depression, the screening a patient receives depends heavily on the individual clinic or telehealth provider, not a standardized FDA label. Ask whether your intake included a cardiovascular history and blood pressure check, since ketamine can raise blood pressure and heart rate, which is a concern for people with uncontrolled hypertension or certain heart conditions. Ask whether the clinic screens for a personal or family history of psychosis, since dissociative and perceptual effects are part of how ketamine works and can be more disorienting for some patients than others.

Researchers have also reported an association between chronic, high-dose ketamine use and a bladder condition sometimes called ketamine-induced cystitis, which can cause urinary urgency, pain, or frequency. This association comes largely from studies of long-term, high-dose recreational use rather than supervised low-dose clinical treatment, but it is still a reasonable question to raise, especially if you expect to be on oral tablets for an extended maintenance period rather than a short course.

Access, Cost, and At-Home Dosing Questions

Oral tablets and troches are sometimes prescribed through telehealth ketamine clinics for take-home, self-administered dosing between in-person or virtual check-ins, a model that does not apply to Spravato because of its REMS in-clinic requirement. If take-home dosing is being offered, ask who you should contact if you feel unsafe during a session, how doses should be stored, and what the plan is if a dose produces stronger or weaker effects than expected. Ask directly whether insurance covers any part of the treatment, since off-label oral ketamine for depression is frequently billed as a self-pay service, unlike Spravato, which has an FDA-approved indication that can support insurance coverage in some plans.

Finally, ask how progress will be measured and when the clinic would recommend stopping, switching routes of administration, or adding other treatment. A clear answer to that question is one of the simplest ways to tell whether a provider has a structured plan versus an open-ended prescription.